Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
Lenalidomide and Dacarbazine (DTIC) in Patients With Metastatic Melanoma
- First Posted Date
- 2006-12-18
- Last Posted Date
- 2016-04-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 28
- Registration Number
- NCT00412581
- Locations
- 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States
Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2006-12-13
- Last Posted Date
- 2017-09-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 39
- Registration Number
- NCT00410605
- Locations
- 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
🇺🇸University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer
- First Posted Date
- 2006-11-23
- Last Posted Date
- 2017-04-20
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 26
- Registration Number
- NCT00403169
- Locations
- 🇺🇸
Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma
- First Posted Date
- 2006-11-10
- Last Posted Date
- 2013-09-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 25
- Registration Number
- NCT00398515
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2006-09-19
- Last Posted Date
- 2016-11-17
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 65
- Registration Number
- NCT00378209
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2006-09-19
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 68
- Registration Number
- NCT00378105
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Lenalidomide for Patients With Myelofibrosis (MF)
- First Posted Date
- 2006-07-17
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT00352794
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes
- Conditions
- Interventions
- First Posted Date
- 2006-07-14
- Last Posted Date
- 2018-09-19
- Lead Sponsor
- Mikkael Sekeres MD
- Target Recruit Count
- 37
- Registration Number
- NCT00352001
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa, Florida, United States
🇺🇸University of California at Los Angeles, Los Angeles, California, United States
🇺🇸Cleveland Clinic Taussig Cancer Instititute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia
- Conditions
- Adult Acute Eosinophilic LeukemiaAdult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monocytic Leukemia (M5b)Adult Acute Basophilic LeukemiaAdult Acute Megakaryoblastic Leukemia (M7)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Erythroleukemia (M6a)Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Interventions
- First Posted Date
- 2006-07-14
- Last Posted Date
- 2022-02-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 41
- Registration Number
- NCT00352365
- Locations
- 🇺🇸
Berdeaux, Donald MD (UIA Investigator), Great Falls, Montana, United States
🇺🇸Great Falls Clinic, Great Falls, Montana, United States
🇺🇸Bozeman Deaconess Cancer Center, Bozeman, Montana, United States
A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2006-05-09
- Last Posted Date
- 2016-03-16
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 40
- Registration Number
- NCT00322985
- Locations
- 🇨🇦
Cancer Care Manitoba, Winnipeg, Manitoba, Canada
🇨🇦Queen Elizabeth II, Health Services Centre, Halifax,, Nova Scotia, Canada
🇨🇦Ottawa Hospital General Campus, Ottawa, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.